Acute myocardial infarction. Acute myocardial infarction
Conditions
Interventions
Intervention 1: Intervention group (Receiving of colchicine):single 2 mg dose (two 1 mg tablets) 1 to 2 hours before percutaneous coronary intervention (PCI). Followed by one 1 mg dose (one tablet) 1
Sponsors
Mazandaran University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1- Adults over 18 years of age 2-Patients who are candidates for PCI
Exclusion criteria
Exclusion criteria: Use of oral corticosteroids and nonsteroidal anti-inflammatory drugs other than aspirin more than 72 hours before or three times the half-life of the drug GFR <30 ml/min and the patient is on dialysis Use of strong CYP3A4/P-glycoprotein inhibitors Chronic use of colchicine or development of tolerance to colchicine Presence of infection or active malignancy in the patient History of myelodysplasia in the patient Participation in other studies Inability to provide information or lack of consent Any factor that the researcher believes may distort the results of the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of Major Adverse Cardiac Events (MACE) in patients after Percutaneous Coronary Intervention (PCI). Timepoint: Monitoring up to 30 days. Method of measurement: MACE questionnaire. | — |
Secondary
| Measure | Time frame |
|---|---|
| Evaluation of inflammatory factors Troponin, CRP. Timepoint: Measurements of the concentrations of the above inflammatory factors will be performed at baseline, as well as one hour after PCI, 6 to 8 hours, 22 to 24 hours, and 30 days after PCI. Method of measurement: Studying the incidence and type of side effects of colchicine. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactHamideh Abbaspour Kasgari
Mazandaran University of Medical Sciences
Outcome results
None listed